InvestorsHub Logo
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

Re: gfp927z post# 4596

Tuesday, 03/13/2007 11:22:51 AM

Tuesday, March 13, 2007 11:22:51 AM

Post# of 52299
We know that Servier can pick three compounds to develop from a limited, subpar roster.

Worrying about whether Servier could somehow--in spite of a complete lack of specialized drug delivery expertise (or any other R&D strengths)-- develop an 'ultra short pulse dosing' release system that does not yet exist, which was suggested as a theoretical alternative by a competitor with dominant IP, in order to deliver currently unsafe compounds...

is not worth my time. It's like buying AstonMartin and worrying about whether Kia might come up with a competitive high-end sports sedan.

NeuroInvestment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News